Compare SYBT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYBT | SRPT |
|---|---|---|
| Founded | 1904 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2009 | 2000 |
| Metric | SYBT | SRPT |
|---|---|---|
| Price | $79.97 | $17.99 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 24 |
| Target Price | ★ $87.60 | $21.64 |
| AVG Volume (30 Days) | 134.9K | ★ 2.5M |
| Earning Date | 10-28-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | ★ 22.11 | N/A |
| EPS | 2.55 | ★ 2.99 |
| Revenue | $23,406,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $15.69 | N/A |
| Revenue Next Year | $9.90 | N/A |
| P/E Ratio | $31.97 | ★ $6.35 |
| Revenue Growth | 3.37 | ★ 15.58 |
| 52 Week Low | $61.51 | $14.68 |
| 52 Week High | $89.22 | $24.68 |
| Indicator | SYBT | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 53.59 |
| Support Level | $75.81 | $18.38 |
| Resistance Level | $82.14 | $19.71 |
| Average True Range (ATR) | 1.75 | 0.91 |
| MACD | 0.53 | 0.13 |
| Stochastic Oscillator | 74.85 | 75.22 |
Stock Yards Bancorp Inc operates as a bank holding company providing commercial banking and wealth management services. Its Commercial Banking segment offers loan and deposit products to consumers and businesses, including retail and mortgage lending, deposit services, online and mobile banking, private banking, commercial and real estate lending, treasury and merchant services, international and correspondent banking, credit cards, and brokerage services through a third-party broker-dealer. Its Wealth Management and Trust (WM&T) segment provides investment management, financial and retirement planning, trust and estate services, and retirement plan management, with WM&T revenue distinguishing the company from similarly sized community banks.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.